Holmes Cheryl L, Landry Donald W, Granton John T
Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Crit Care. 2003 Dec;7(6):427-34. doi: 10.1186/cc2337. Epub 2003 Jun 26.
Vasopressin is emerging as a rational therapy for vasodilatory shock states. Unlike other vasoconstrictor agents, vasopressin also has vasodilatory properties. The goal of the present review is to explore the vascular actions of vasopressin. In part 1 of the review we discuss structure, signaling pathways, and tissue distributions of the classic vasopressin receptors, namely V1 vascular, V2 renal, V3 pituitary and oxytocin receptors, and the P2 class of purinoreceptors. Knowledge of the function and distribution of vasopressin receptors is key to understanding the seemingly contradictory actions of vasopressin on the vascular system. In part 2 of the review we discuss the effects of vasopressin on vascular smooth muscle and the heart, and we summarize clinical studies of vasopressin in shock states.
血管加压素正逐渐成为治疗血管舒张性休克状态的合理疗法。与其他血管收缩剂不同,血管加压素还具有血管舒张特性。本综述的目的是探讨血管加压素的血管作用。在综述的第1部分,我们讨论经典血管加压素受体的结构、信号通路和组织分布,即V1血管受体、V2肾受体、V3垂体受体和催产素受体,以及嘌呤受体的P2类。了解血管加压素受体的功能和分布是理解血管加压素对血管系统看似矛盾作用的关键。在综述的第2部分,我们讨论血管加压素对血管平滑肌和心脏的影响,并总结血管加压素在休克状态下的临床研究。